| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
In the mollusk central nervous system, Phe-Met-Arg-Phe amide (FMRFa) works on K+ channels in sensory neurons, motor neurons, and neuroendocrine neurons. Phe-Met-Arg-Phe amide triggers a unique K+ current characterized by a mix of voltage and receptor-dependent gating mechanisms, both of which are required to open the channel [1]. Phe-Met-Arg-Phe amide (1 μM) significantly reduced glucose-stimulated (300 mg/dL) insulin release (p<0.005) and somatostatin release from isolated perfused pancreas (p<0.01). Phe-Met-Arg-Phe amide (FMRF-NH2) (1 and 10 μM) has no influence on glucagon secretion during hypoglycemia (50 mg/dL), hyperglycemia (300 mg/dL), or arginine stimulation influence (5 mM)[2].
|
|---|---|
| ln Vivo |
Phe-Met-Arg-Phe amide (FMRFamide) enhances growth hormone production in conscious OVX rats. The presence of Phe-Met-Arg-Phe amide-like immunoreactivity in hypothalamic neurons suggests a role in hypothalamic control of anterior pituitary function. 15 minutes after injection, a 200 ng (313.8 pmol) FMRFamide (2 uL) infusion dramatically raised plasma GH. After 5 minutes and continuing for up to 30 minutes, 400–800 ng (627–1255) of FMRFamide are shown to increase growth hormone [3].
|
| References |
[1]. Kits KS, et al. Phe-Met-Arg-Phe-amide activates a novel voltage-dependent K+ current through a lipoxygenasepathway in molluscan neurones. J Gen Physiol. 1997 Nov;110(5):611-28.
[2]. Sorenson RL, et al. Phe-met-arg-phe-amide (FMRF-NH2) inhibits insulin and somatostatin secretion and anti-FMRF-NH2 sera detects pancreatic polypeptide cells in the rat islet. Peptides. 1984 Jul-Aug;5(4):777-82. [3]. Ottlecz A, et al. Phe-Met-Arg-Phe-amide (FMRFamide) stimulated growth hormone secretion in conscious OVX rats. Neuropeptides. 1987 Feb-Mar;9(2):161-7. |
| Molecular Formula |
C33H44F6N8O8S
|
|---|---|
| Molecular Weight |
826.806687355042
|
| CAS # |
159237-99-7
|
| Related CAS # |
Phe-Met-Arg-Phe, amide;64190-70-1;Phe-Met-Arg-Phe, amide acetate;152165-14-5
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
S(C)CC[C@@H](C(N[C@H](C(N[C@H](C(N)=O)CC1C=CC=CC=1)=O)CCC/N=C(\N)/N)=O)NC([C@H](CC1C=CC=CC=1)N)=O.FC(C(=O)O)(F)F.FC(C(=O)O)(F)F
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~120.95 mM)
H2O : ~20 mg/mL (~24.19 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.02 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.02 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.02 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2095 mL | 6.0473 mL | 12.0947 mL | |
| 5 mM | 0.2419 mL | 1.2095 mL | 2.4189 mL | |
| 10 mM | 0.1209 mL | 0.6047 mL | 1.2095 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
